Abstract:
A once-a-day controlled release formulation of a water soluble drug is described which includes: (a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder; and a second layer which comprises a membrane comprising a pH dependent polymeric material; and (b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder and a second layer which comprises a polymeric membrane and a alkaline earth metal stearate which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to said water soluble drug; and (c) a unit dose containment system.
Abstract:
A wide angle, atomizing-type of cleaning device for windshield of car is disclosed. The cleaning solution storage tank is heated by the energy of the engine of the car and by means of a liquid pump and an air pump, together with nozzles, the cleaning solution is atomized to clean the windshield by rapidly dissolving of the oil mist and moisture. The wiper faces little resistance from the surface of the windshield as the entire surface is provided with the atomized cleaning solution from the tank.
Abstract:
A method of forming an integrated circuit device using ion implantation to improve the adhesion of plasma nitride to spin-on-glass is achieved. Semiconductor device structures are provided in and on a substrate where conductive connections are planned between the device structures and planned conductive traces overlying a planned interlevel dielectric layer. An insulating oxide layer is deposited overlying the device structures. A spin-on-glass layer is coated overlying the insulating oxide layer. The spin-on-glass layer is dried. The spin-on-glass layer is ion implanted to form an amorphous, silicon rich, adhesion layer at the top surface of the spin-on-glass layer. The spin-on-glass layer is cured. A first plasma-enhanced silicon nitride layer deposited overlying the adhesion layer of the spin-on-glass and completing the interlevel dielectric layer. Via openings are etched through to the top surfaces of the semiconductor device. A conductive layer is deposited to fill the via openings and is etched to form the conductive traces. A second plasma-enhanced silicon nitride layer is deposited to complete the integrated circuit.
Abstract:
A high Q inductor and its forming method is disclosed. In this forming method, a semiconductor substrate is first provided with a trench formed thereon. The trench is defined by dry etching and formed to a depth of 3˜5 &mgr;m. A material having a higher resistivity than that of the semiconductor is then provided to fill the trench. The material can be formed by first depositing an epitaxy layer with a lower dopant concentration than that of the semiconductor substrate by several orders of magnitude on the semiconductor substrate, then etching back the epitaxy layer to expose the surface of the semiconductor substrate. Thereafter, a dielectric layer is formed on the semiconductor substrate and the trench, and an inductor winding is formed on the dielectric layer above the trench to form the high Q inductor.
Abstract:
A scanner includes a bottom cover, a top cover, at least one elastic member, at least one rod, an optical module and at least one spacer. The elastic member is disposed on the bottom cover. The rod is supported by the elastic member. The optical module is movably supported by the rod. The spacer is disposed between the top cover and the rod so that the optical module moves parallel to the top cover.
Abstract:
A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.
Abstract:
A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of:(a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and(b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.
Abstract:
A controlled release dosage formulation is described which is based on a combination of:(a) a compressed tablet core which contains an alkyl ester of a hydroxy substituted naphthalene derivative a pharmaceutically acceptable, water swellable polymer and an osmotic agent; and(b) an outer coating layer which completely covers the osmotic core and comprises a pH sensitive coating agent and a water insoluble polymer.
Abstract:
A unit dosage form of capsule, tablet or the like is composed of a large number of pellets made up of two or more populations of pellets or particles. Each pellet contains a core containing the therapeutic drug and a water soluble osmotic agent. A water-permeable, water-insoluble polymer film encloses each core. Incorporated into the polymer film is a hydrophobic, water insoluble agent which alters the permeability of the polymer film. The film coating of each population of pellets differs from the coating of every other population of pellets in the dosage form in the rate at which water passes through to the core and the rate at which drug diffuses out of the core. The osmotic agent dissolves in the water, causing the pellet to swell and regulating the rate of diffusion of drug into the environment of use. As each population of pellets releases its drug into the environment sequentially, the effect is to provide a series of pulsatile administrations of the drug from a single dosage form.
Abstract:
A pharmaceutical composition for oral administration of potassium salt in a form not irritating to the gastrointestinal mucosa comprises tablets or capsules of micropellets of a potassium salt, such as potassium chloride. The micropellets are coated with a permeable polymer comprising a low viscosity (10 cp.) ethylcellulose in combination with triacetin. This coating provides a strong film resistant to breakage during formation of tablets and filling of capsules. The protective coating of the micropellets prevents the early release of potassium ions, while the tablet or capsule disintegrates and the micropellets are dispersed within the lumen of the gastrointestinal tract. As water passes through the permeable but insoluble coating, potassium ions are gradually eluted into the fluid of the tract over a period of many hours, thereby allowing time for the ions to be absorbed from the tract before high, irritating ion concentrations can form.